CoChat

Long-acting amylin analogues for the management of obesity

Mathiesen, David S., Bagger, Jonatan I., Knop, Filip K. · 2022 · Current Opinion in Endocrinology, Diabetes & Obesity
Cited by 36

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Purpose of review: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. Recent findings: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to – at least partly – be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide. Summary: Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/med.0000000000000716

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 36

Metadata

Authors
Mathiesen, D. S., Bagger, J. I., & Knop, F. K.
Venue
Current Opinion in Endocrinology, Diabetes & Obesity
Published
2022-01-21
Volume
29
Issue
2
Pages
183-190
ISSN
  • 1752-296X (ISSN-L)
  • 1752-2978
OpenAlex
W4206996811
Cited by
36
References
17
FWCI
3.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-acting amylin analogues for the management of obesity. https://app.cochat.ai/papers/10.1097/med.0000000000000716
The paper
Mathiesen, D. S., Bagger, J. I., & Knop, F. K. (2022). Long-acting amylin analogues for the management of obesity. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000716

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.